Opportunity knocks for companies threatening the innovation barrier at EULAR

Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the world’s biggest pharma companies continue to earn the largest slice of their revenue.

But the burning question for those companies remains unchanged: what’s next?

Biosimilar companies are already starting to grab chunks of the revenue that has brought in billions for innovative drugmakers from biologics introduced in the late 1990s, particularly in Europe, and the cliff-edge dates for competitors to enter the US market have started to elapse too, or to grow uncomfortably close.